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Abstract 
 
Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive and incurable neurodegenerative disorder 
 
that targets upper and lower motor neurons and leads to fatal muscle paralysis. Mutations in the superoxide dismutase 
1 (SOD1) gene are responsible for 15% of familial ALS cases, but several studies have indicated that SOD1 
dysfunction may also play a pathogenic role in sporadic ALS. SOD1 induces numerous toxic effects through the 
pathological misfolding and aggregation of mutant SOD1 species, hence a reduction of the levels of toxic variants 
appears to be a promising therapeutic strategy for SOD1-related ALS. Several methods are used to modulate gene 
expression in vivo; these include RNA interference, antisense oligonucleotides (ASOs) and CRISPR/Cas9 
technology. 
Areas covered: This paper examines the current approaches for gene silencing and the progress made in 
 
silencing SOD1 in vivo. It progresses to shed light on the key results and pitfalls of these studies and highlights   
the future challenges and new perspectives for this exciting research field. 
Expert Opinion: Gene silencing strategies targeting SOD1 may represent effective approaches for familial and 
 
sporadic ALS-related neurodegeneration; however, the risk of off-target effects must  be  minimized,  and  
effective and minimally invasive delivery strategies should be fine-tuned. 
 
Keywords: amyotrophic lateral sclerosis; ALS; superoxide dismutase 1; SOD1; gene  silencing;  RNA 
interference; antisense oligonucleotides; CRISPR; Cas9. 
 
 
 
 
 
 
 
 
Article Highlights 
 
• Autosomal dominant mutations in the superoxide dismutase 1 (SOD1) gene, which  encodes  a  free radical 
scavenger protein, are responsible for 15% of familial ALS cases. 
• Mutant SOD1 exerts its toxic effect via pathological misfolding and aggregation, which has also been shown 
to occur in sporadic ALS. 
• SOD1 aggregates may induce the spread of disease within the CNS through seeded aggregation and a prion-
like transmission mechanism. 
• Gene silencing can be achieved through different techniques, namely,  antisense  oligonucleotides  (ASOs), 
RNA interference (RNAi) with small RNAs (miRNAs, shRNAs, and siRNAs)  and  CRISPR/Cas9 gene 
editing. 
• ASOs do not require delivery systems, whereas RNAi- and CRISPR/Cas9-based tools need to be paired with 
viral vectors, the most commonly used being retroviruses, lentiviruses, adenoviruses and adeno-associated 
viruses. 
• ASOs, AAV-delivered shRNAs and miRNAs and SOD1-targeted CRISPR/Cas9 systems  have  been tested 
in SOD1 mouse models with generally satisfying results. ASO-based therapy was  shown  to  exhibit a good 
safety profile in humans in a phase I clinical trial and a phase I trial of an SOD1-directed miRNA construct 
will start soon. 
• The most significant concerns regarding these therapeutic strategies include the risk of off-target effects, 
reduced allele specificity resulting in dangerous wild-type SOD1 inhibition, and the risk of immune 
activation. 
• Future attempts to overcome these challenges may take advantage of gene knockout-and-replace approaches 
and nanoengineered delivery tools. 
 
 
 
 
1. Introduction 
 
Amyotrophic lateral sclerosis (ALS) is a fatal motoneuronal disorder that causes progressive degeneration of  
upper and lower motor neurons in the primary motor cortex, brainstem, and spinal cord [1]. The degeneration    
and loss of motor neurons cause progressive weakness and atrophy  of skeletal  muscles, which usually  progress  
to paralysis and death within 3 to 5 years [1]. Currently, no effective therapy exists for this disease. ALS is  
defined as sporadic (sALS) when it occurs in individuals with no family history and is termed familial (fALS) 
when at least two people from the same family are affected. Sporadic ALS represents 85-90% of all cases and    
has a median age of onset ranging from 58-63 years [1–3]. Familial ALS accounts for the remaining 10-15% of 
cases and has a slightly younger age of onset (47-53 years) [2]; potential causative mutations have been    
identified in more than 50 genes. The most commonly mutated genes, accounting for almost 75% of fALS cases, 
are C9orf72, TARDBP, FUS and SOD1 [1]. Dominantly inherited mutations in the SOD1 gene were the first to    
be described and are linked to 15% of fALS cases [4]. Over 180 genetic variants of SOD1 have been identified     
in patients with ALS (http://alsod.iop.kcl.ac.uk/; http://databrowser.projectmine.com; http://alskp.org) [5–8]. The 
vast majority of pathogenic variants are heterozygous; however, rare homozygous variants have been described 
[9,10]. 
 
The SOD1 gene is located on chromosome 21q22.11 and encodes Cu/Zn superoxide dismutase. The SOD1 
protein acts as an antioxidant enzyme by converting two superoxide anions, which are byproducts of cellular 
respiration with oxidant action, into hydrogen peroxide and oxygen [11]. Human SOD1 forms a homodimer,  
with each monomer binding one zinc ion and one copper ion and carrying a disulfide bond. Full metalation and 
disulfide bonding enhance protein stability in the cytoplasm and favor dimerization [12,13]. These 
posttranslational modifications are essential for the acquisition of its catalytic properties. SOD1 maturation 
appears to be mediated by copper chaperone for superoxide dismutase (Ccs1), which seems to determine SOD1 
activation through copper insertion and disulfide bond formation [14–16]; however, its exact role has not been 
firmly established (thoroughly reviewed in [17]). SOD1 is present both in the cytosol and in the mitochondrial 
intermembrane space and controls the levels of oxidizing species, which are mostly produced by the 
 
 
 
 
mitochondrial respiratory chain and NADPH oxidases [18–21]. The presence of mutant SOD1 protein 
(mutSOD1) is strongly linked to motor neuron diseases. The pathogenic mechanism seems to be a 
gain-of-function mechanism that involves the formation of toxic SOD1 aggregates, although the mechanisms 
underlying SOD1 aggregation and toxicity have not yet been completely elucidated. Although changes in the 
levels of enzyme activity were initially believed to be the primary pathogenic mechanism, it was observed that 
disease severity does not correlate with levels of dismutase activity [22]. Further insights come from the 
observation that while transgenic mice overexpressing the SOD1 protein present a typical ALS phenotype, SOD1-
null mice do not [23,24]. This finding, together with the autosomal dominant transmission of SOD1 mutations, 
suggests that a gain of toxic function of SOD1 is the main pathogenic hit. Therefore, it has been hypothesized that 
mutSOD1 may induce disease by adopting an unstable conformation, which is reflected by the failure of 
downstream pathways in several cell types within the CNS [25]. Furthermore, recent evidence supports the role of 
SOD1-mediated toxicity and oxidative damage in the pathogenesis of sALS [26–28]. 
 
2. Molecular and cellular mechanisms of SOD1-mediated toxicity 
 
 
 
2.1 SOD1 misfolding and toxicity in familial ALS with SOD1 mutation 
 
As mentioned above, inherited SOD1 mutations may exert their detrimental effect by inducing toxic changes in 
protein conformation, which in turn may cause the formation of toxic aggregates that accumulate in   
mitochondria, thus disrupting several cellular processes, including scavenging of free radicals, protein quality 
control and controlled degradation, mitochondrial function, axonal transport, mRNA splicing and membrane 
excitation [29–32]. It was found that a short epitope located within the N-terminal region of mutSOD1 called the 
Derlin-binding region  (DBR) binds with high specificity  to  the cytosolic carboxyl-terminal region of Derlin-1, 
an endoplasmic reticulum (ER)-resident protein [33], causing ER stress, a mechanism known to play a role in 
several neurodegenerative diseases, including ALS [34]. A specific monoclonal antibody directed against DBR 
(MS785) is able to discriminate mutSOD1 from wild-type SOD1 (wtSOD1) and nontoxic mutants, suggesting  
that DBR might be masked in wtSOD1 and become exposed in mutSOD1 due to a pathogenic mutation-induced 
 
 
 
 
conformational change [35]. Furthermore, it was found that mutSOD1 is more prone to hydrophobicity than the 
wild-type protein and that different expositions of hydrophobic residues correlate with SOD1 aggregation levels 
[36]. These properties might also represent potential therapeutic targets, as reverting or inhibiting conformational 
alterations and/or changes in hydrophobicity  might attenuate SOD1 toxicity. MutSOD1 monomers are believed   
to cause protein toxicity by reducing proteasome and chaperone activity and allowing abnormal protein-protein 
interactions [31]. Abnormalities in the chaperone system, such as the inhibition of protein disulfide isomerase 
(PDI), which is responsible for disulfide bond formation, have been shown to result in increased aggregate 
formation [37]. Indeed, increased inactivation of PDI by S-nitrosylation has been demonstrated to accompany 
disease progression in ALS [38]. Furthermore,  another chaperone protein,  macrophage  migration inhibitory 
factor (MIF), has been found to inhibit the adhesion of mutSOD1 to mitochondria and consequent SOD1 
accumulation within mitochondria and the ER, thus exerting protective effects [39]. Remarkably, MIF appears to 
be differentially expressed in astrocytes and motor neurons, with lower levels in motor neurons possibly  
explaining the increased susceptibility to noxious effects in ALS [39]. 
Aggregate formation in turn seems to disrupt different cellular pathways, causing mitochondrial dysfunction, 
excitotoxicity, oxidative stress, ER stress, axonal transport disruption, and intercellular prion-like propagation  
[32]. These findings highlight the potential benefit of therapies aimed at reducing the presence of mutant SOD1 
aggregates, which might prove useful not only for fALS patients but also for sALS patients, as we will discuss in 
the following paragraph. 
 
2.2 SOD1 misfolding and aggregation in sporadic ALS 
 
Notably, evidence suggests that the aggregation and spreading of misfolded proteins, including SOD1, is a key 
feature of sALS as well [40,41]. Indeed, wild-type SOD1 (wtSOD1) may gain a toxic function following 
changes in protein conformation induced by aberrant posttranslational mechanisms such as demetallation and 
overoxidation [26–28]. A common conformational epitope was detected in oxidized wtSOD1 and in 
fALS-linked mutant SOD1, but not in wtSOD1, and oxidized wtSOD1 was found to inhibit axonal transport in a 
manner similar to mutant SOD1 [28]. Furthermore, misfolded “mutant-like” SOD1 protein has been observed in 
 
 
 
 
postmortem spinal cord samples from sALS patients [42]. These observations may have implications for 
therapeutic translation. Indeed, it has been found that the knockdown of both wtSOD1 and mutSOD1 in 
astrocytes derived from sALS and fALS patients results in a reduction in MN-directed astrocytic toxicity [43]. 
SOD1 expression in different glial cell types, such as astrocytes [43,44], microglia [45] and oligodendrocytes 
[46], has been shown to contribute to ALS onset and progression, highlighting the pleiotropy observed in ALS. 
 
2.3 Glia-mediated toxicity in ALS 
 
Non-cell-autonomous toxicity has been demonstrated in several rodent-derived and human-derived primary 
astrocyte lines (reviewed in [47]). In two cellular ALS models, for example, extensive death of primary spinal  
cord motoneurons and  embryonic stem cell-derived  motoneurons is induced when cells  are cultured on 
astrocytes expressing human mutant SOD1 or exposed to conditioned medium derived from astrocytes    
expressing mutant SOD1 [48,49]. Moreover, mutant astrocytes have been found to exert a toxic effect on motor 
neurons through the secretion of a soluble Bax-dependent toxic factor [49], which was later found to induce an 
increase in membrane excitability and voltage-sensitive sodium channel activity [50,51]. Astrocytes also trigger 
motor neuron death in cocultures through the induction of mitochondrial dysfunction [52]. Another study 
demonstrated that human embryonic stem cell (hESC)-derived astrocytes activate inflammatory response  
pathways in the presence of SOD1 mutation and that this effect is reversed by treatment with antioxidant 
compounds [53]. Furthermore, induced pluripotent stem cell (iPSC)-derived astrocytes generated from fALS and 
sALS patients are able to trigger motor neuron death in coculture models [43,54,55]. In addition, the 
transplantation of mutant SOD1-expressing astrocyte precursors into the spinal cord of wild-type rats has been 
shown to result in cellular engraftment and subsequent mild and nonprogressive motor neuron degeneration [56]. 
 
2.4 Spreading of misfolded SOD1 
 
Seeded aggregation and cell-to-cell transmission are known properties of mutant SOD1 protein. Both mutSOD1 
and wtSOD1 have the ability to seed the aggregation of the wild-type protein [57]. Exosomal transmission has 
been demonstrated for both mutant and wild-type SOD1 aggregates [57], while mutSOD1 can otherwise be 
 
 
 
 
released in neurosecretory vesicles through a chromogranin A- and B-mediated pathway [58]. Aggregates may 
then enter cells via micropinocytosis [59]. 
Furthermore, recent data seem to indicate that SOD1 aggregates may induce disease spreading within the CNS 
through a prion-like transmission mechanism. In transgenic murine models, SOD1 is able to form aggregate 
seeds that, upon inoculation into the spinal cord, spread along the neuraxis and initiate premature fatal motor 
neuron disease [60]. Moreover, spinal cord homogenates prepared from mice expressing mutSOD1 
(SOD1-G93A and SOD1-G37R) induced severe pathology and an earlier onset of symptoms when directly 
injected into the spinal cords of mice carrying a mutated SOD1-G85R protein fused to yellow fluorescent protein 
(G85R-YFP mice) [61]. 
Taken together, these results might explain the initial focal manifestations of ALS and the subsequent contiguous 
spread that is usually observed in the clinical course of the disease. In addition, they provide a rational basis for 
silencing SOD1, as reducing the production of the mutant protein could potentially  act directly on SOD1    
toxicity, on the amount of aggregation, seeding and intercellular spreading, and on a variety of downstream 
pathways [32]. 
 
3. Therapeutic silencing of SOD1 in ALS: Rationale and limits 
 
 
 
Since it was first discovered that gene expression can be directly modulated in vivo by exogenously delivered 
compounds, a new array of therapeutic opportunities has emerged. As discussed above, SOD1 represents an 
intriguing target for silencing strategies given its autosomal dominant inheritance and the evidence for the toxic 
role of the mutant protein. Conformational changes, seeded aggregation and possibly prion-like transmission   
seem to be the main causes of SOD1 dysfunction, while downstream degeneration is mediated by, among others, 
ER and oxidative stress, mitochondrial dysfunction and alterations in mRNA splicing and axonal transport [29– 
32]. Furthermore, SOD1 seems to be implicated not only in fALS cases but also in sporadic cases, with mutant 
sALS-SOD1 sharing common epitopes with fALS-SOD1 [28]. Notably, the knockdown of SOD1 in astrocytes 
 
 
 
 
was shown to be able to attenuate neurotoxicity in an in vitro model, suggesting a possible beneficial role of 
SOD1-directed therapies in different types of cells in the CNS [43]. 
These findings notwithstanding, safety concerns arise from the controversial role of loss-of-function mutations in 
SOD1. Although a loss-of-function mechanism was previously thought to be the molecular basis of fALS    
[62,63], evidence from studies in animal models have mostly  rejected this hypothesis. Transgenic SOD1  
knockout models do not show features of motor neuron disease, although they do present increased susceptibility 
to motor neuron loss after axonal damage, elevated oxidative stress and acceleration of age-related muscle loss 
[64–66]. Nevertheless, the current belief that SOD1 silencing does not exert pathogenic effects was challenged    
by a recent report of the first known case of inherited SOD1 deficiency [67]. The patient carried a homozygous 
truncated SOD1 variant that led to loss of enzymatic activity, as demonstrated by a functional assay, and to a 
phenotype characterized by hyperekplexia, ataxia, muscle hypotony and intellectual disability [67]. 
While the identification of this mutation supports the potential toxicity of a reduction in SOD1, this hypothesis 
was not confirmed by safety studies thus far. Animal and human trials of therapeutic silencing of SOD1 have not 
revealed significant safety concerns. The antisense oligonucleotide (ASO) ISIS 333611, which targets SOD1,   
was tested in the SOD1-G93A transgenic mouse model and caused a decrease in SOD1 mRNA and protein    
levels in the CSF and a slight prolongation of survival without inducing major side effects [68]. On these   
grounds, a human phase I clinical trial of intrathecally delivered ISIS 333611 was attempted; 21 patients    
received treatment, while 8 patients received sham treatment. Following treatment, SOD1 CSF concentrations 
were within 12% of the original value on average [69]. The most common adverse events were post lumbar 
puncture syndrome and back pain, which were likely related to the infusion procedure, and the rate did not differ 
between the treatment and placebo groups. Moreover, the number of adverse events did not increase with 
increasing doses of ISIS 333611. However, limited conclusions can be inferred from this study given the small 
study sample and the low treatment doses received by patients. Another silencing technique based on RNA 
interference (RNAi) that utilized a microRNA (miRNA) was tested in healthy nonhuman primates; the miRNA 
induced no serious adverse reactions and showed good tolerability and is therefore now ready to enter the    
clinical trial phase [70]. 
 
 
 
 
Overall, the effect of reducing or silencing SOD1 on motor neurons and other cell types in the CNS, as well as    
on functional neural networks, has not been completely clarified so far. Given the role of SOD1 in the   
metabolism of reactive oxygen species (ROS), its depletion could lead to the persistence of or even an increase    
in oxidative damage. As described above, findings from both animal and early human studies do not seem to 
indicate the presence of side effects linked to SOD1 depletion. However, this could be partly explained by the 
differences between animal and human physiology and by the low doses of silencing compounds used in the 
human trial. On the other hand, it can be argued that silencing efficiency is never complete, and that residual 
enzyme activity might be sufficient to prevent evident and immediate damage. It is difficult to predict whether a 
reduction in SOD1 can cause long-term complications related to chronic low-level oxidative stress and  
consequent inflammation. The preventative use of antioxidant compounds, such as N-acetylcysteine, can 
counteract this potential side effect [71]. SOD1 mimetics have also been tested for their antioxidant properties 
against radiation-induced damage and have shown an acceptable safety profile [72]. Another potential strategy is 
the combination of gene silencing and replacement techniques, through which the reduction in the levels of 
endogenous SOD1 is balanced by the expression of an artificially delivered silencing-resistant SOD1 gene, as 
described by Xia and colleagues [73]. Further preclinical and clinical studies are needed to better characterize    
the impact of SOD1 silencing on neurons and glial cells and determine whether residual SOD1 activity might 
efficiently maintain SOD1-dependent physiological processes. 
 
 
 
4. Strategies for gene silencing 
 
 
 
In recent decades, increasing knowledge of the translational and posttranslational machinery has led to the 
identification and synthesis of molecules that are able to modulate gene expression by altering mRNA translation 
and pairing (Figure 1). These techniques include antisense oligonucleotides, RNAi and CRISPR/Cas9. 
 
4.1 Antisense oligonucleotides (ASOs) 
 
 
 
 
 
 
ASOs are short (8-50 bp) synthetic single-stranded RNA molecules that trigger the RNase H< mediated cleavage of 
a complementary RNA target [74]. Several subclasses of ASOs have been created by altering the structure of ASOs, 
and morpholino phosphorodiamidate ASOs (PMOs), in which a morpholine ring in substituted for a ribose, have 
shown the highest stability and resistance to nucleases [74,75]. ASOs have been widely studied in the field of 
neurology, and ASO-mediated therapies were recently approved by the FDA for two neurological diseases: Spinraza 
for spinal muscular atrophy (SMA), a previously incurable motor neuron disease, and eteplirsen for Duchenne 
muscular dystrophy (DMD) [76,77]. A limitation of ASO technology is the reduced biodistribution and 
bioavailability of ASOs, which makes choosing an appropriate delivery site and method extremely important for 
reaching target sites to elicite the desired effects. 
 
4.2 RNA interference 
 
The development of RNAi stemmed from the discovery that only a small fraction of the human genome is translated 
into protein products, while the vast majority (more than 85%) is transcribed into noncoding RNAs (ncRNAs), the 
main function of which appears to be the regulation of gene expression. 
Among ncRNAs, the most known and studied by far are miRNAs, small interfering RNAs (siRNAs) and short hairpin 
RNAs (shRNAs), which are small double-stranded RNA sequences that may originate endogenously (miRNAs) or 
exogenously (siRNAs and shRNAs) [78]. Small RNAs work by integrating into the RNA-induced silencing complex 
(RISC) and recognizing the complementary mRNA target sequence. Once the target is recognized, Argonaute (AGO) 
proteins, the effector proteins of the RISC, achieve silencing by blocking  translation or by degrading the mRNA 
[78]. This endogenous pathway can be exploited by delivering exogenous compounds that are able to participate in 
this mechanism to silence target mRNAs (Figure 1). For instance, viral vectors that penetrate the nucleus can induce 
the transcription of either miRNAs or shRNAs, which are then processed via this pathway. siRNAs can be delivered 
as exogenous reagents and directly interact with the RISC complex. These nonendogenous silencing reagents have 
been termed “artificial” or “synthetic.” 
 
 
 
 
RNAi holds great potential as a therapy for neurological diseases, and approved RNAi-based therapies include 
patisiran, an siRNA used for the treatment of amyloidosis [79,80]. The greatest limitations of RNAi are its poor 
stability, as all RNAi are susceptible to the action of serum nucleases, and off-target effects, which is the 
inappropriate silencing of nontarget mRNAs [78]. Different chemical modifications of the original RNA structure, 
such as modifications of the sugar moiety of siRNAs as a way to reduce instability and reduce immune system 
activation [78], have been tested for their ability to reduce these side effects. Backbone modification, such as 
replacement with phosphothioate and boranophosphate, may improve stability, and resist the actions of nucleases 
and cellular uptake [81,82]. In addition, modifications of siRNA terminal strands with cholesterol, folate or other 
peptides were investigated for their ability to aid in membrane crossing to the targeting specific cells or organs [83]. 
 
4.3 CRISPR/Cas9 
 
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 nuclease 
(Cas9) system is an RNA-guided DNA editing tool derived from natural bacterial defense mechanisms that creates 
double-strand breaks (DSBs) in target sites in the genome, allowing for precise genome editing [84]. In bacteria, 
viral DNA sequences are recognized by two constructs, CRISPR targeting RNA (crRNA) and transactivating  RNA 
(tracrRNA) [84]. Cas9 is a gene editing protein derived from Streptococcus pyogenes . In the CRISPR/Cas9 system, 
crRNA and tracrRNA are fused into a single guide RNA (sgRNA) that locates the target DNA sequence, while Cas9 
is the gene editing effector. Within the sgRNA, there are two recognition sequences, one of which recognizes the 
complementary target sequences and the other of which, a photospacer adjacent motif (PAM), matches with the 
complementary PAM at the 3’ end of the target sequence to initiate cleavage. These two processes aim to reduce off-
target effects, although they cannot abolish them completely. Different structural modifications, which were 
thoroughly reviewed previously [85], have been studied for their ability to further reduce off-target effects. 
 
 
 
 
Recently, two innovative treatments based on the modification of autologous T-cells with CRISPR-Cas9 technology, 
CAR< T (chimeric antigen receptor engineered T cells) and TCR< T (T cell receptor engineered T cells), have been 
approved for cancer therapy [86]. 
 
4.4 Delivery strategies for molecular therapies 
 
A considerable issue regarding molecular therapy is optimal delivery, as high intracellular entry is required to 
maximize clinical effects. In neurological diseases, an additional obstacle is the identification of the target site, as 
the high functional specialization of different CNS areas combined with low blood-brain barrier (BBB) permeability 
make the spreading of effector molecules difficult [87]. 
ASOs do not require associated delivery systems, but they are not able to cross the BBB; thus, they need to be 
injected into the CNS [88]. Conversely, RNAi therapy-, CRISPR-and gene therapy-based strategies require delivery 
tools [87]. Given their small dimensions, high lipophilicity and reduced binding to serum proteins, molecules such 
as polymeric nanoparticles (NPs) and lipid complexes might serve this function  [87]. Nevertheless, viral vectors, 
particular retroviruses, lentiviruses, adenoviruses and adeno-associated viruses (AAVs), which are able to infect host 
cells and replicate through the host machinery (and are thus able to cross the BBB and easily reach target sites), are 
the most commonly used tools. 
In the field of neurological diseases, the most widely used and studied vectors are AAV vectors due to their potential 
to infect both replicating cells, such as astrocytes, and nonreplicating cells, such as neurons, and their ability to ensure 
stable gene expression with each delivery. Furthermore, AAVs have a low immunogenic profile and show no 
pathogenicity [89]. Cell tropism of AAVs varies according to their capsid composition; thus, different serotypes can 
be distinguished based on their specific distribution. AAV2, AAV5, AAV8 and AAV9 are able to transfect neurons, 
while AAV5 and AAV1 are capable of transfecting astrocytes and oligodendrocytes as well [90,91]. 
AAV9 has been shown to have a unique ability to cross the BBB. Murine studies on the intravenous administration 
of AAV9 combined with green fluorescent protein (GFP) have shown diffuse distribution of GFP in the brains and 
spinal cords of newborn mice but scarce distribution mostly limited to astrocytes in adult mice [92]. Conversely, 
 
 
 
 
intrathecal administration leads to increased GFP expression [93,94], though limited to anterior horn alpha-motor 
neurons, while ventral horn interneurons appear to be transgene-negative [95]. Based on these results, Miyanohara 
and colleagues hypothesized the involvement of an additional regulatory barrier system (besides the BBB) that 
prevents the penetration of the virus into deeper spinal compartments from the intrathecal space and suggested that 
this system could be the pia mater. Thus, they studied the subpial (SP) delivery of AAV9-GFP or AAV9-RFP (red  
fluorescent protein) in adult rats and pigs, which resulted in a wider distribution of the transgene in the spinal 
parenchyma and descending and ascending axons [95]. A recent study also tested subpial delivery of AAV9-shRNAs 
in animals with satisfactory results [96]. Thus, SP delivery could represent a more powerful and efficient delivery 
method if adequately implemented. Currently, local laminectomy is required, making this delivery method unsuitable 
for clinical trials; however, the use of SP delivery could allow reduced frequency of administration. 
The first AAV2-delivered gene therapy, voretigene neparvovec (AAV2-hRPE65v2), was approved in 2017 for 
RPE65-related retinal diseases [97]. Voretigene is administered by subretinal injection and delivers human RPE65 
cDNA to retinal pigment epithelial cells. Furthermore, in 2019, onasemnogene abeparvovec (trade name 
Zolgensma), an AAV9-based gene therapy designed to deliver a functional copy of the human survival motor neuron 
(SMN) gene to motor neurons, was approved by the FDA for the treatment of SMA in patients aged <2 years [98]. 
A single injection resulted in significant improvements in survival in treated patients, who survived beyond 20 
months of age and did not require ventilation until this point. Compared to controls, these patients also showed a 
slower decline in motor function and improved acquisition of motor milestones and thus developed a milder 
phenotype. Outcomes appeared to correlate positively with an earlier age of treatment administration. However, 
long-term follow-up studies are still needed to evaluate the degree of motor decline at later stages and the potential 
long-term complications. 
 
Once the best vector for the selected therapy is chosen, another aspect to consider is the administration route. In the 
case of highly localized pathology, such as the substantia nigra in Parkinson’s disease, the striatum in Huntington's 
disease and the cerebellum in spinocerebellar ataxia, local injection might be an effective method, at least in 
 
 
 
 
preclinical models, and ensure high transgene expression at the injection site. However, degeneration in ALS is 
characterized by a diffuse distribution along the neuraxis, including the cortex, brainstem and anterior horns of the 
spinal cord. Indeed, the injection of an shRNA-expressing AAV into the spinal cord results in reduced transduction 
and no clinical improvement in animals [99]. Other methods that has been tested is the injection of a vector into 
skeletal muscle, which causes subsequent internalization in peripheral nerves and retrograde transport, and direct 
injection into large peripheral nerves [100–102]. These techniques, however, have limited effect and are also difficult 
to translate into clinical practice given the high number of injections that are required. Furthermore, the high doses 
that are necessary would pose significant safety issues given their potential to cause both local and systemic immune 
reactions, a high risk of immunization and systemic off-target effects. 
Another approach is intravenous administration. As described above, some AAV serotypes have the capacity to cross 
the BBB, and the intravenous route has been tested with conflicting results [102–106]. This method allows for 
repetitive administration given its noninvasive nature, but it is limited by low CNS penetrance with a concomitant 
risk of peripheral tissue transduction and immunogenicity. 
Conversely, several groups have chosen to deliver constructs by intrathecal administration, which results in high 
overall cell transduction efficiency and good distribution along the neuraxis. However, intrathecal delivery is 
invasive and might not be suitable for repeated dosing, although it allows for satisfactory diffusion within the  CNS. 
Finally, as mentioned above, another delivery method is subpial administration, which was successfully tested in 
animal models [96]. 
All these methods have been exploited by researchers (Table 1), and the best results have achieved by intrathecal, 
intravenous and intramuscular injections. Our group used a combined intrathecal and intravenous delivery method 
and obtained good results, which may be explained by the combination of central and peripheral actions [40]. 
 
Another issue to be discussed is the cell type that should be targeted. As described in detail above, previous studies 
have established that the presence of mutant SOD1 protein in glial cells can speed disease progression; however, for 
the development of motor neuron disease, SOD1 needs to be present in motor neurons as well [45,47]. Thus, 
 
 
 
 
selective SOD1 silencing in motor neurons may not be sufficient to induce sustained and significant amelioration, 
and other cell types, astrocytes in particular, should be targeted to attain an optimal effect. 
Another important factor to consider is the optimal time window for intervention. Transgenic rodents with the SOD1-
G93A mutation display pathological hallmarks of the disease in the early postnatal period. Similarly, motor neurons 
derived from transgenic embryos show increased membrane excitability in cultures [107–111]. Furthermore, 
observational studies in animals have shown that clinical symptoms manifest several months  after the appearance 
of the first pathological changes, probably due to the presence of intracellular compensatory mechanisms that later 
fail because of aging or traumatic/noxious injury [108]. Imaging studies in ALS patients seem to confirm the presence 
of early metabolic and degenerative cell-specific alterations [112]. However, the absence of specific disease 
biomarkers makes it extremely difficult to identify and diagnose ALS before  it becomes clinically evident in the 
absence of a known family history or genetic hit. Thus, experimental efforts should focus on defining instrumental 
and biological hallmarks of early disease to allow prompt diagnosis and enrollment of patients in clinical trials. 
Conversely, it is still unclear whether there is a point after which silencing SOD1 is no longer effective. 
 
5. Experimental trials of SOD1 silencing 
 
 
 
Several strategies for treating ALS by silencing SOD1 have been tested at both the preclinical and clinical levels 
(Table 1). 
 
5.1 Antisense oligonucleotides 
 
As discussed before, ASOs may be able to reduce the concentration of the mutant protein by binding to the target 
mRNA and promoting its degradation. SOD1-directed ASOs were first studied in 2006 in the SOD1-G93A 
transgenic mouse model, inducing a slight increase in survival (10 days, compared to the untreated group) [68]. 
Furthermore, our group tested morpholino-oligonucleotides (MOs) targeting SOD1 both in rodent and human fALS-
derived iPSCs [40]. The MOs were able to silence SOD1 expression by up to 80% both in vitro and in vivo; 
 
 
 
 
this level of silencing is one of the highest ever reported in the symptomatic stage. MOs were injected both locally 
and systemically and ameliorated neuromuscular function and the survival of treated mice. Moreover, MO treatment 
increased the number of motor neurons and axons in the spinal cord and ventral spinal roots, reduced the presence 
of astrogliosis and activated microglia, and caused morphological changes and reductions in GFAP, s100beta 
(markers of astroglia) and Iba1 (a marker of activated microglia). In addition, a reduction in the presence of misfolded 
SOD1 was detected by immunocytochemistry with specific antibodies. This result has important implications, as 
misfolding of SOD1 has also been shown to occur in sALS patients. Another group tested SOD1 ASOs in transgenic 
mice and rats with good results on survival and neuromuscular function [113]. 
Following these preclinical results, a randomized, placebo-controlled phase I trial of intrathecally injected tofersen 
(also called ISIS 333611, BIIB067, and IONIS SOD1Rx) was conducted in patients with SOD1 mutation, and there 
was a similar rate of adverse events between the two groups (88% in the placebo group vs. 83% in the treatment 
group) [69]. The most common events were postlumbar puncture syndrome, back pain, and nausea, and no dose-
limiting toxic effects or serious events were reported. Thus, given the good safety profile, an open-label trial aimed 
at evaluating the clinical response was started and is now ongoing (NCT03070119 at www.clinicaltrials.gov). 
Given the invasiveness of intrathecal administration and the possibility of complications, especially in cases of 
repeated dosing, a calcium phosphate-lipid nanocarrier able to encapsulate ASOs was developed and tested in 
zebrafish. Immediately and up to 29 hours after systemic injection, ASO-carrying nanoparticles were detectable in 
the blood immediately and in the spinal cord [114]. Further improvements in nanoparticle-aided delivery could thus 
help avoid invasive intathecal administration. 
  
5.2 RNA interference: shRNAs/siRNAs 
 
The use of hSOD1-shRNAs, siRNAs and miRNAs has proven effective in several in vivo models (Table 1). Different 
viral vectors, including adeno-associated viruses (AAVs), lentiviruses (LVs), rabies-glycoprotein-pseudotyped 
lentiviruses (RGP-LVs), and adenoviruses (AVs), have been tested. shRNAs and siRNAs provided efficient 
transduction and increased survival [99–101,103,115–117], and lower levels of human 
 
 
 
 
SOD1 in the spinal cord of treated animals, although only on the side ipsilateral to the injection [116], were 
demonstrated by indirect immunofluorescence and immunoblotting studies [103,116]. The same results were 
observed in the motor cortex after local intracortical injection of the construct [116]. Foust and colleagues also 
detected a reduction in astrogliosis, but not in microgliosis, in treated mice [103]. Nonetheless, subsequent studies 
detected reductions in both astrogliosis and microgliosis (using GFAP and Iba1 staining on lumbar cord sections), 
as well as an improvement in motor neuron survival after treatment in the presymptomatic stage [96,118]. Bravo-
Hernandez and colleagues also observed the preservation of spinal alpha-motor neurons, of interneurons  and of 
neuromuscular junctions after subpial treatment, in comparison with sham-operated animals [96]. These results 
expand the potential cellular targets for SOD1 silencing from only lower motor neurons, which are often the preferred 
target, to other cell types as well. Interestingly, the injection of AAV9-hSOD1-shRNA into mice in the symptomatic 
stage (P85) resulted in greater astrocyte transduction (approx. 50%) than neuronal transduction (approx. 8%) [103]. 
In the same study, the intrathecal delivery of AAV9-shRNA to healthy nonhuman primates (Cynomolgus macaques) 
by lumbar puncture was able to efficiently transduce cells and reduce SOD1 at all spinal cord levels with a caudal to 
rostral gradient [103]. This finding is relevant as it sets the stage for human clinical trials of AAV9-mediated therapy. 
 
As shown in Table 1, the different shRNAs and siRNAs used in previous studies were delivered at different postnatal 
ages (from P0 to 109), at the embryonic stage or via cross-breeding with shRNA-expressing transgenic mice 
[73,119]. The data show a certain degree of correlation between age of treatment and outcomes; in some studies, 
earlier silencing seemed to result in increased survival [96,100,103,119]. However, comparisons between different 
studies is hindered by the variety of delivery methods used. The reduced efficacy may have also been due also to 
differences in the vectors used and in the delivery method; the intramuscular and intravenous injection of AAV6 
resulted in low levels of motor neuron transduction and no clinical benefit [102]. It can be hypothesized that this was 
the consequence of the inability of AAV6 to efficiently cross the BBB. 
 
 
 
 
These findings notwithstanding, some questions arise when considering these studies. In most of the studies, shRNAs 
with high silencing efficacy were used and elicited significant therapeutic benefits, but the shRNAs targeted both 
wild-type and mutant genes. In transgenic animals, this nonselective silencing does not interfere with the therapeutic 
effect, as animals expressed human mutant genes as well as endogenous genes. Therefore, the robust therapeutic 
effects may have been due to the high silencing efficacy of the shRNAs used. The use of an allele-specific shRNA 
in one experiment resulted in modest silencing, although some of the factors that  contributed to this reduction in 
transgenic mice are not present in humans (i.e., a high number of mutant SOD1 transgene copies and higher steady 
state protein levels) [73]. Nevertheless, these results demonstrate that allele-specific silencing is feasible and can be 
further improved. To avoid a pathological decrease in the wild-type allele, Xia and colleagues developed a strategy 
based on the combined use of gene editing and gene replacement [120]. In their study, both mutant and wild< type 
genes were inhibited by shRNAs, and wild< type SOD1 was replaced by designed RNAi-resistant wild< type SOD1 
genes through the insertion of silent mutations. This strategy resulted in the inhibition of endogenous SOD1 and 
replacement with the exogenous SOD1 gene in vitro. Certainly, the translation of this strategy to in vivo models 
would need to address potential off-target effects and toxicity concerns, but this technique could prove useful in 
avoiding the risk of excessive target gene silencing. 
 
Another major obstacle in bringing RNAi therapy from the bench to the bedside is the lack of an in vivo biomarker 
of therapeutic response. To overcome this barrier, Iannitti and colleagues, analyzed the CSF of transgenic mice for 
the presence of hSOD1 protein after treatment with AAV9-shRNA and found a 63% decrease compared to untreated 
controls [118]. Notably, these data suggest that CSF SOD1 protein levels could be used as a reliable biomarker to 
verify target engagement and correct dosing in future clinical trials in SOD1-associated  ALS patients. 
 
5.3 RNA interference: miRNAs 
 
Vectors expressing artificial miRNAs present fewer problems than their shRNA counterparts in the process of 
clinical translation, as they have a lower risk of toxicity, exhibit a safer immunogenic profile and produce fewer 
 
 
 
 
off-target effects [25]. Moreover, the vectors can be tailored to allow tissue-specific or conditioned expression by 
Pol II promoters or coexpression with fluorescent markers such as GFP or DsRed [121]. They can also be chained 
to sequentially transcribe multiple miRNAs from the same promoter, an approach termed combinatorial RNAi 
(coRNAi); this enhances silencing efficacy when the same miRNA sequence is repeated and allows the simultaneous 
targeting of different mRNAs by joining different miRNA sequences [121]. 
Taking advantage of these multiple properties, several studies have tested artificial miRNAs in SOD1 transgenic 
models (Table 1) [105,122–124]. Different vectors, including AAV6, AAV9 and AAVrh10, have been used and 
have produced promising results in terms of transduction efficiency and outcomes. For example, a single intravenous 
or intrathecal injection of AAVrh10 carrying hSOD1-miRNA in the symptomatic stage resulted in widespread 
distribution of the construct along the spinal cord in most mice and the amelioration of ALS phenotypes, delaying 
disease onset, extending survival and increasing the preservation of motor skills [105,122]. Notably, in the same 
study, AAVrh10 and AAV9 performed much better than AAV1, 2 and 8 and were able to achieve widespread 
transduction of motor neurons, astrocytes and oligodendrocytes along the spinal cord and into the brainstem in mouse 
and nonhuman primate models [122]. 
To evaluate the therapeutic responses of different cell types, Dirren and colleagues generated two constructs with 
different serotype/promoter combinations that predominantly targeted either motoneurons or astrocytes [123]. They 
found that following the injection of the AAV vectors into both newborn and adult mice, motor neurons were most 
protected when SOD1 was mainly silenced in motoneurons, with 83-92% of motoneurons still present in end-stage 
mice treated at birth, while astrocyte-specific silencing led to the survival of 54-62% of motor neurons. However, 
the astrocytic expression of miR SOD1 normalized motor performance and electrophysiological parameters, thus 
supporting a critical role of the astroglial expression of mutated SOD1 in the decline of neuromuscular function. 
 
To further the translatability of miRNA-based techniques, Borel and colleagues delivered an 
 
AAVrh10-CB/U6/H1-miR SOD1 construct with or without GFP to healthy macaques by intrathecal catheter [70]. 
The constructs led to profound and reproducible SOD1 silencing and demonstrated a good safety profile, as 
 
 
 
 
measured by the abundance of the predicted mature miRNA compared to that of alternate species (a low ratio 
suggests a risk of potential off-target effects) and the guide/passenger strand ratio (which also limits the risk of off-
target effects). The production of neutralizing antibodies was detected after the intrathecal administration of 
AAVrh10, but it did not correlate with the cellular immune response and did not interfere with therapeutic 
efficacy. However, the cellular immune response characterized by IFN-γ-secreting T cells in humans cannot be 
precisely reproduced in animals. Excitingly, the FDA recently approved an investigational drug application (IND 
#17179) for a pilot phase I clinical trial of this construct in humans, which will hopefully elucidate whether its 
safety profile in humans, mirrors that in animals. 
5.4 CRISPR/Cas9 
 
In recent years, CRISPR/Cas9 has gained increasing popularity as a genome editing tool due to its simplicity and 
relative precision. To date, CRISPR/Cas9 has been tested on fALS SOD1 iPSCs [125], but only one group attempted 
in vivo treatment in an SOD1 mouse model through the intravenous administration of an AAV9 vector encoding the 
Cas9 nuclease with an sgRNA targeting the mutant SOD1 gene [106]. This treatment yielded a reduction in the 
expression of mutant SOD1 protein and SaCas9 in the spinal cord, although this decrease was primarily limited to 
ChAT-expressing motor neurons. Clinically, it resulted in delayed disease onset, improved muscle function and 
extended survival in treated mice, although it was not able to slow ALS progression once the disease was established. 
The authors speculated that this may have been due to inefficient SOD1 disruption in astrocytes, which would 
eventually cause the abolishment of motor neuron support and give rise to secondary degeneration. Thus, optimizing 
Cas9 expression in different cell types (for example, by selecting a different Cas9 ortholog or creating specialized 
promoter sequences) appears to now be a major target for future CRISPR/Cas9 studies aimed at silencing SOD1. 
Another issue highlighted by this study is lack of specificity, as the sgRNA used was unable to distinguish between 
mutant and wild-type human SOD1 [106]. The potential risks are off-target effects and excessive SOD1 silencing. 
Nevertheless, future studies might develop an allele-specific CRISPR system configured to target disease-causing 
SOD1 mutations or a gene knockout-and-replace therapy, such as one involving shRNAs [120], to overcome these 
hurdles. 
 
 
 
 
 
 
6. Conclusions 
 
In recent years, gene editing, and silencing strategies have managed to traverse the “valley of death” between 
preclinical and clinical research and have thus initiated a new era in the fields of genetic diseases. However, while 
the mechanism of action and endpoints might be relatively easy to establish in cases of monogenic diseases with a  
well-known pathological basis, such as TTR amyloidosis, or diseases with an early and rapid onset, such as SMA 
and DMD, navigating the sea between the bench and the bedside might prove extremely perilous in the case of a 
disease like ALS. Indeed, several pieces of knowledge that allow for precise definitions of therapeutic timing, 
delivery strategy, monitoring and endpoint are lacking for ALS; in humans, the disease often becomes evident when 
the neurodegeneration has already spread diffusely, and reliable, validated biomarkers of disease onset and 
progression are still lacking. Furthermore, although several cellular functions and pathways have been found to be 
disrupted, the exact relationships between neurodegeneration, neuronal loss, the impairment of glial trophic functions 
and neuroinflammation and their timing remain elusive. Taken together, these observations might frustrate many 
researchers, and we are ourselves astonished by the paucity of current clinical trials for ALS treatment worldwide 
considering the large number of compounds that have been tested at the preclinical level. Surely, we are missing 
some key pieces in the complex puzzle of ALS pathology and pathogenesis. In this regard, studying familial ALS is 
advantageous as we have at least a partial explanation of the initiation of the pathological process. More specifically, 
SOD1 represents an interesting target because it is caused by a dominant heterozygous mutation with Mendelian 
inheritance, and aggregates of mutant SOD1 protein have been shown to cause both motor neuron and glial 
degeneration in vitro and in vivo [25,32,40,47,60]. 
Various approaches aimed at reducing the levels of mutant SOD1 protein have been tested in vivo, in most cases 
yielding positive results. For instance, mice treated with ASOs demonstrate a slight improvement in survival and 
neuromuscular function. Similarly, RNAi was studied in rodent models and was shown to have a beneficial impact 
on survival, especially when delivered intravenously or intrathecally in the presymptomatic or embryonic stages.  In 
addition, shRNAs and miRNAs were found to increase neuroprotection and reduce gliosis at the histological level. 
Several vectors, including AAV6, AAV9 and AAVrh10, were used for their delivery. CRISPR/Cas9 was 
 
 
 
 
tested in a single mouse model and induced prolonged survival. Overall, preclinical studies highlighted  the efficacy 
of these therapies in reducing the levels of misfolded SOD1 and increasing motor neurons survival and 
neuroprotection. Some of them also detected a reduction in astrogliosis and microgliosis. Results were influenced 
by the age of animals when treatment was administered and by the mode of delivery. As regards the former, an earlier 
treatment was associated with the best outcomes, while concerning the latter, intrathecal and intravenous delivery 
were the most successful delivery routes. However, a potential concern is the risk of off-target effects, with 
concomitant excessive reduction of wild-type SOD1 protein. As discussed previously, the biological effects  of this 
depletion are not completely known, but it may provoke an increase of free radicals and consequent oxidative stress. 
This was not observed in animal studies, and a safety trial conducted on macaques (a model closer to human 
physiology) demonstrated a good safety profile, especially in terms of the absence of an immune cellular response 
following administration and of the off-target effect. 
As regards clinical trials, Tofersen, an antisense oligonucleotide, was evaluated in a randomized, placebo-controlled 
phase I study in humans, and compared to sham controls, patients treated with Tofersen  showed no significant 
adverse events. An open-label study is now ongoing to assess its efficacy in an extended time window. Moreover, 
after being demonstrated to be safe in nonhuman primates, an AAVrh10-CB/U6/H1-miRNA SOD1 construct 
recently gained investigational drug status and will soon be evaluated in a phase I clinical trial. The effective impact 
of these drugs on disease severity and progression remains a major question to be answered. 
In preclinical studies, the key factors seem to be early administration and the selection of a delivery method that 
allows efficient penetration into the CNS and into the deeper layers of the spinal cord. In support of this observation, 
many authors have pointed out that most therapies extend the disease-free period rather than delaying progression, 
thus advocating for the need to identify and validate biomarkers of early disease. Nowadays, identifying ALS before 
it becomes clinically evident in more than one body region is extremely hard, but the timing of administration of 
SOD1 suppressing therapies seems to be a key factor. Future studies should  concentrate on establishing which is the 
“point of no return”, after which it is not possible to revert the disease process nor to delay neurodegeneration and 
clinical progression. 
 
 
 
 
 
 
7. Expert Opinion 
 
SOD1 silencing techniques hold a great potential for a still incurable disease such as ALS. However, in order to 
bridge the gap between bench and bedside, these methods need to pass several challenges, such as demonstrating a 
good safety profile and a satisfactory efficacy and finding an effective and practical delivery method. To date, they 
have shown promising results in some preclinical models. Notwithstanding these findings, in our opinion, animal 
studies conducted to date have several limitations. First, the most widely used model is a high-copy SOD1-G93A 
transgenic mouse; the therapeutic effects observed in this line likely result from the high silencing efficacy of the 
constructs used, which often have low allele specificity. It is still unclear whether a lower efficacy would still result 
in a widespread effect and a clinical benefit when translated to humans. Furthermore, it has long been believed that 
while SOD1 misfolding and accumulation are responsible for ALS, SOD1 depletion is not associated with any known 
pathological effect. However, a recent report of a patient with inherited SOD1 deficiency challenged this belief [67]. 
Functional assays demonstrated a reduction in SOD1 activity in this patient. This discovery makes allele specificity 
a primary goal in the development of human silencing techniques. Another potential approach for avoiding a toxic 
reduction in the expression of the target gene is the combination of gene silencing and gene replacement, an 
innovative technique that has proven efficacious in a mouse model of ALS [120]. This approach is currently being 
used in other neurological diseases as well; for example, our group is currently studying a combined approach 
involving the codelivery of an shRNA with an engineered RNAi-resistant gene for the treatment of congenital 
MFN2-related Charcot-Marie-Tooth (data under publication). This strategy is, in our opinion, extremely promising 
for counteracting the risk of wild-type allele silencing. Another challenge that has to be overcome, before these drugs 
may enter the general market, is finding a safe but also economically sustainable method of production, in order to 
allow a high number of patients to access them. 
Nevertheless, despite the hurdles that we have exposed, the first steps in moving some of the illustrated approaches 
to the clinic have been achieved. Given their simplicity and their ability to be directly administered to the CNS 
without the concerns associated with viral vectors, ASOs will likely soon progress to the next stages of clinical 
research and possibly reach the general market. Some interesting nanoengineering strategies aimed at improving 
 
 
 
 
the delivery process and avoiding repeated invasive lumbar punctures are currently being studied [114]. However, 
in our opinion, the short half-life of these compounds makes RNAi and CRISPR-based approaches more  appealing, 
give their potential to induce sustained construct expression. Thus, it is essential to further evaluate delivery methods 
and safety. Considering that as a whole ALS is complicated, as opposed to monogenic diseases, the ideal SOD1 
silencing reagent would probably have the ability to cross the BBB and to act on different areas of the CNS and on  
different cell types. RNA-interference techniques combined with AAVs are probably the closest  to this goal, as they 
proved able to transfect different cell types after injection (both intravenous and intrathecal) at different clinical 
stages in preclinical studies. One compound is also entering clinical trials right now (IND#17179). However, several 
issues needs to be addressed, such as safety in humans and efficacy after the disease is clinically established. To this 
regard, future research will need to focus on the development of biomarkers of early disease to protect against motor 
neuron degeneration in a timely manner. Many studies have demonstrated that most SOD1-silencing therapies 
prolong the disease-free period rather than  delaying  progression. Furthermore, as we discussed above there seems 
to be a correlation between time of intervention and outcome in animal models. In our opinion, treating patients once 
the disease is clinically established might not revert the pathogenic process, even if a reduction in SOD1 levels is 
achieved. Thus, acting early seems to be essential for therapeutic success. 
Overall, we believe that silencing strategies represent the most exciting and promising approaches for SOD1-related 
ALS and may succeed where all other drugs have failed thus far, provided that researchers will be able to find 
answers to these unsolved questions that still burden ALS research. Other innovative therapeutic strategies have been 
studied against ALS, however they are unlikely to be ready for bedside use in the following years; for instance, stem 
cell transplantation [126]. Considering other approaches, no pharmaceutical compound proved able to prolong 
survival by more than some months [3,127]. Given these points, and the tremendous progresses made by gene 
silencing and editing research in the past years, we believe that the techniques discussed in this review might advance 
faster than others in the foreseeable future. Hopefully, in the next five years we might withstand SOD1-targeting 
ASOs passing clinical trials and entering general market, provided that the correct ALS population to target is 
identified; in addition to that, RNAi-based therapies might also enter the clinical trial phase. 
 
 
 
 
Nowadays, increasing interest is being given by the scientific community to the development of CRISPR/Cas9 
technology, so we hypothesize that CRISPR-based studied might catalyze efforts and funding and thus establish a 
solid preclinical ground and be ready for clinical phase by five or, maybe, ten years. We also think that genomic 
studies might soon identify other potential genetic targets which influence disease development in sporadic ALS, 
such as genes involved in neuroinflammation and protection from oxidative injury, allowing for the application of 
gene modulation also in these patients. We find unrealistic that in ten years a definitive treatment for sporadic ALS 
will be available, but it is reasonable to believe that some disease-modifying agents will be ready for genetic forms, 
such as SOD1-related ALS. SOD1 silencing techniques might help us to reach this goal. 
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Figure Legend 
 
 
Figure 1. Endogenous pathways may be exploited to achieve therapeutic gene silencing. Primary miRNAs (Pri< 
miRNAs) are transcribed from miRNA genes and cleaved by Drosha into hairpin precursors (pre< miRNAs). Pre< 
miRNAs are transported to the cytoplasm by exportin-5 and subsequently cleaved by Dicer, giving rise to miRNAs. 
miRNAs engage with the RNA< induced silencing complex (RISC) to promote RNA degradation or translational 
arrest. Vector< delivered synthetic miRNAs (smiRNAs) and short hairpin RNAs (shRNAs) need to penetrate the 
nucleus to enter the upstream miRNA pathway. Small interfering RNAs (siRNAs) and single< stranded siRNAs (ss< 
miRNAs) act directly in the cytoplasm. Antisense oligonucleotides (ASOs) complementary to nuclear pre< mRNAs 
or cytoplasmic mRNAs exploit the RNAse-mediated pathway, binding to complementary sequences to induce their 
degradation. This process may occur both in the nucleus and in the cytoplasm. CRISPR/Cas9 acts on double-stranded 
DNA, causing breakage at target sites in the genome. 
 
 
 
 
Table. 1. Preclinical in vivo and clinical studies of SOD1 silencing. 
This table focuses on animal and human studies of SOD1 silencing, highlighting the impact on survival in terms of 
percentage increase. Abbreviations: AV, adenovirus, AAV; adeno-associated virus; CMV, cytomegalovirus; ICV, 
Intracerebroventricular; LV, lentivirus; MO, morpholino oligonucleotides; P, postnatal age; RGP, 
rabies-glycoprotein-pseudotyped. 
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e in 
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Current 
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Antisense oligonucleotides 
SOD1 -r141692 hSOD1-G93A-tg-Rat 12 P65 ICV 8% Smith et al., 
2006 
/ 
Bare-MO hSOD1-G93A-tg-mice 11 P85 ICV, 
intraven 
ous 
+19-2 
1 days 
Nizzardo et 
al., 2016 
/ 
Bare-MO, 
Modified-MO 
hSOD1-G93A-tg-mice N/A P0, P3, P6 ICV, 
intraperit 
oneal 
N/A 
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analys 
is) 
- / 
Modified-MO hSOD1-G93A-tg-mice N/A P120 Intraven 
ous 
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is) 
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placebo-controlled, 
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al 
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Miller at al., 
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hSOD1-G93A-tg-mice 10 P45 Intramusc 
ular 
Increase 
d 
preservat 
ion of 
grip 
strength 
in the 
injected 
side 
Miller et 
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us 
0 Towne et 
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into 
sciatic 
nerve 
8% Wu et al., 
2009 
/ 
AAV6-H1-shRNA hSOD1-G93A-tg-mice 8 P1-P15 Intramusc 
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us 
20% Borel et 
al., 2016 
/ 
AAVrh10-U6-miR - N/A - - 21% -  
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